Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index, and 3 are not checked yet; 16 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE ε4 allele carriers but not in noncarriers. CONCLUSIONS: Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).
Verified 2026-10-06 · 3 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 8 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [11] Sperling R Salloway S Brooks DJ Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 2012 11 241 9 22305802 PMC4063417 source
The Methods identify the scans as coming from phase 2 bapineuzumab studies 201 and 202 and their extension study 251. The Results report that ARIA-E incidence increased with both bapineuzumab dose and the number of APOE ε4 alleles. Page numbers are not available in our copy. (LLM, conf=0.94)
- Supportedcites [13] Salloway S Sperling R Gilman S A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 2009 73 2061 70 19923550 PMC2790221 source
The Abstract reports that MRI-detected vasogenic edema was more frequent in higher bapineuzumab dose groups. The Safety section reports increasing edema rates with APOE ε4 gene dose: 4.3% with zero copies, 7.1% with one, and 33.3% with two. The supplied passages do not give page numbers. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) identify 3D6 as an antibody that reduced plaque burden in PDAPP transgenic mice. They do not report that 3D6 improved memory; the paper’s mention of improved object-recognition performance concerns a different antibody directed against the midportion of Aβ. (LLM, conf=0.86)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The Results report that 3D6 treatment protected synapses in transgenic PDAPP mice, and Figure 4 (Discussion; page not specified) reports improved synaptophysin levels. The paper does not report a memory test or show that 3D6 improved memory; synaptic protection does not establish that outcome. (LLM, conf=0.84)
- Could not verifycites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The antibody-results passage (section labeled Abstract; page unavailable) reports that 3D6 precipitated soluble Aβ and prevented a synaptic-plasticity deficit. The memory experiment in the same section used normal rats and did not test 3D6. Searches for 3D6 and for antibody treatment in transgenic mice found no passage showing that 3D6 improved their memory. (LLM, conf=0.76)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Results section, “The N-terminal anti-Aβ mAb 3D6 acutely reverses CFC deficit in Tg2576 mice” (Fig. 6), reports that 3D6 completely reversed a contextual fear-conditioning deficit in transgenic mice overexpressing human amyloid precursor protein. The Introduction identifies 3D6 as the murine antibody from which bapineuzumab was humanized. Together, these passages support the attributed improvement in a memory-related task. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [2] Bateman RJ Xiong C Benzinger TL Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 2012 367 795 804 [Erratum, N Engl J Med 2012;367:780.] 22784036 PMC3474597 source
The Results (Combined Model) report Aβ deposition detected at least 15 years before expected symptom onset in mutation carriers. The Discussion also says amyloid deposition probably occurs years or decades before dementia symptoms in sporadic Alzheimer’s disease. (LLM, conf=0.93)
- Supportedcites [26] Jack CR Jr Knopman DS Jagust WJ Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol 2010 9 119 28 20083042 PMC2819840 source
In “Biomarker abnormalities precede clinical symptoms,” the paper says that calculated rates from serial PiB imaging indicate Aβ-plaque accumulation might begin as much as two decades before clinical symptoms in individuals destined to develop dementia. That supports the cited claim’s qualified wording, “probably starts many years before.” The separate treatment claim in the citing sentence is attached to citation 28, not this source. (LLM, conf=0.94)
- Not checked yetcites [27] Villemagne VL Burnham S Bourgeat P Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study Lancet Neurol 2013 12 357 67 23477989 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 source
The Results and Discussion (page unavailable) identifies 3D6 among antibodies previously effective at reducing plaque burden in vivo. The paper describes those brain plaques as containing Aβ, supporting the attributed preclinical reduction in brain Aβ. (LLM, conf=0.88)
- Supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 source
The Results report significantly reduced brain Aβ levels after passive immunization with N-terminal anti-Aβ antibodies. The Methods identify 3D6 as an anti-Aβ(1–5) antibody, and the Figure 4 caption confirms that PDAPP mice received 3D6 as a passive immunization treatment. Page numbers are unavailable in our copy. (LLM, conf=0.91)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The passage on antibody co-administration (section labeled Abstract; page unavailable) reports that 3D6 almost completely precipitated soluble Aβ from extracts of human Alzheimer’s brains. That is an ex vivo finding, not evidence that administering 3D6 reduces Aβ levels in the brain in preclinical animals. (LLM, conf=0.78)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Abstract reports that preclinical studies of 3D6, the murine form of bapineuzumab, demonstrated resolution of Aβ plaque and vascular burdens in transgenic mice. The Introduction likewise describes enhanced clearance of insoluble Aβ in the brain and cerebral vasculature, supporting the claim that 3D6 reduces brain Aβ. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
Table 1 in Results and Discussion (page unavailable) reports that 3D6 binds amyloid plaques in PDAPP mice, supporting binding to deposited Aβ. It does not report that 3D6 binds oligomeric or monomeric Aβ; the aggregated-versus-soluble binding measurements concern other antibodies. (LLM, conf=0.82)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The antibody-generation section identifies 3D6 as an antibody against Aβ(1–5), and the methods describe its use to stain amyloid plaques. Our copy does not establish that 3D6 binds each of the fibrillar, oligomeric, and monomeric forms of Aβ; searches for those forms found no binding results. (LLM, conf=0.83)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The paper reports that 3D6 immunoprecipitated soluble Aβ from Alzheimer’s brain extracts; its discussion of 3D6-immunoprecipitated material includes dimers and monomers (Abstract, page unavailable). Our copy does not show that 3D6 binds fibrillar Aβ, so the claim’s full list of forms is not supported. (LLM, conf=0.84)
- Partly supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 sourceExperimental — accuracy not yet measured
The section “Binding of the N-terminal antibody 3D6 to soluble Aβ species” reports that 3D6 binds soluble, oligomer-enriched Aβ. The Introduction describes clearance of insoluble Aβ, but the passages do not establish direct binding to fibrillar or monomeric Aβ. Those two specified forms are therefore not fully supported by this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 57 claims and to verify the 18 references still open.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following the completion of the first two studies, which revealed no treatment efficacy on either cognitive or functional outcomes, further trials were halted (Salloway et al., 2014).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bapineuzumab was the first monoclonal antibody to target Aβ in AD using a passive immunotherapy technique.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this idea, studies have shown that extracellular amyloid deposition correlates poorly with the degree of cognitive decline in AD [10], in agreement with the results obtained in clinical trials showing that Aβ-targeted immunotherapies removing Aβ deposition in the brain do not result in cognitive improvement [99].”
From Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology (2023) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further trials were discontinued after the first two trials were completed and yielded no treatment effect on either cognitive or functional outcomes [41].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Items 401–500 of 1,014
Metabolomics-based screening of salivary biomarkers for early diagnosis of Alzheimer's disease
Liang, Q., Liu, H., Zhang, T., Jiang, Y., Xing, H., & Zhang, A.-H. (2015) · RSC Advances · doi:10.1039/c5ra19094k · Cited by 81
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
APOE effects on regional tau in preclinical Alzheimer’s disease
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., Mormino, E. C., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00590-4 · Cited by 80
“This may also partially explain why in early clinical trials for AD dementia patients, which did not yet routinely assess amyloid status, e4 carriers declined more rapidly than non-e4 carriers [24].”
ResultSelf-citationChételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80
“5% in APOE4 carriers versus 36% in non-carriers (Salloway et al., 2014; Liu et al., 2015).”
BackgroundResultTen Challenges of the Amyloid Hypothesis of Alzheimer’s Disease
Kepp, K. P. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160550 · Cited by 81
“However, another antibody, Bapineuzumab, has been found not to improve cognition [142] and produce adverse effects [143] even though it does lower A (cid:2) levels [144].”
Ketter, N., Brashear, H. R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., & Arrighi, H. M. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160216 · Cited by 77
“…review (Final Read) wasperformedinpatientswithmild-to-moderateAD, and who had completed their participation in the two Phase III studies of intravenous bapineuzumab in APOE (cid:2) 4 allele carriers or noncarriers (Clin-icalTrials.gov: NCT00574132; NCT00575055) as described in Salloway et al. [16].”
InfluentialSelf-citationStem cell therapy in Alzheimer’s disease: possible benefits and limiting drawbacks
Alipour, M., Nabavi, S. M., Arab, L., Vosough, M., Pakdaman, H., Ehsani, E., & Shahpasand, K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-018-4499-7 · Cited by 63
Scholtzova, H., Chianchiano, P., Pan, J., Sun, Y., Goñi, F., Mehta, P. D., & Wisniewski, T. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0101-2 · Cited by 77
Niki, K., Yahara, M., Inagaki, M., Takahashi, N., Watanabe, A., Okuda, T., Ueda, M., Iwai, D., Sato, K., & Ito, T. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.598161 · Cited by 80
“More recently, a series of phase 3 trials of new dementia drug candidates (Salloway et al., 2014; Honig et al., 2018; Wessels et al., 2019) ended in failure, highlighting the limitations of drug therapy for dementia.”
BackgroundWong, L. R., & Ho, P. C. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12836 · Cited by 78
“Of note is the clearance of Ab from the brains of apolipoprotein E (APOE) e4 carriers in phase 3 clinical trials with bapineuzumab that has failed to provide clinical benefit,([4]) suggesting that treatments which alter Ab levels may be ineffective in mild-to-moderate AD.”
BackgroundFinding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
Jutten, R. J., Sikkes, S. A. M., Van der Flier, W. M., Scheltens, P., Visser, P. J., Tijms, B. M., & Initiative, F. T. A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012022 · Cited by 81
Burns, T. C., Li, M. D., Mehta, S., Awad, A. J., & Morgan, A. A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.021 · Cited by 79
Zhao, Y., Chen, X., Wu, Y., Wang, Y., Li, Y., & Xiang, C. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00140 · Cited by 83
“However, there are no effective therapies for AD involving pharmacological agents that target either Aβ or tau aggregation inhibitors (Doody et al., 2014; Salloway et al., 2014; Lovestone et al., 2015; Gauthier et al., 2016).”
BackgroundDo anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?
Hunter, S., & Brayne, C. (2017) · Journal of Negative Results in BioMedicine · doi:10.1186/s12952-017-0066-3 · Cited by 77
“It is essential BC05 Raised against Aβ (35–43); recognises Aβ42 and Aβ43; epitope not well described Cross reacts with N-terminal truncated peptides including P3; does not recognise Aβ40; used in commercial ELISA kits for the detection of Aβ42 [28, 44] BA27 Raised against Aβ (1–40) Recognises Aβ40; 100-1000x more reac…”
BackgroundInfluentialCurrent directions in tau research: Highlights from Tau 2020
Sexton, C., Snyder, H., Beher, D., Boxer, A. L., Brannelly, P., Brion, J., Buée, L., Cacace, A. M., Chételat, G., Citron, M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12452 · Cited by 79
DiFrancesco, J. C., Longoni, M., & Piazza, F. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00207 · Cited by 78
Barnes, D. E., Mehling, W. E., Wu, E. Y., Beristianos, M. H., Yaffe, K. S., Skultety, K. M., & Chesney, M. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0113367 · Cited by 94
“[7–12] Therefore, it is critically important to study alternative approaches that allow individuals with dementia to maintain physical function, cognitive function and quality of life to the greatest degree possible throughout the disease process.”
BackgroundLiu, A., Jain, N., Vyas, A., & Lim, L. W. (2015) · eLife · doi:10.7554/elife.04803 · Cited by 76
“001), 305 retention interval (F(2,145)=16.”
Clark, D. G., McLaughlin, P. M., Woo, E., Hwang, K., Hurtz, S., Ramirez, L., Eastman, J., Dukes, R., Kapur, P., DeRamus, T. P., et al. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.001 · Cited by 80
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
Castello, M. A., Jeppson, J. D., & Soriano, S. (2014) · BMC Neurology · doi:10.1186/s12883-014-0169-0 · Cited by 77
“At the same time, even the most recent bapineuzumab trial continues to be limited by edema formation, a symptom highly associated with cerebral amyloid angiopathy, the damaging vascular amyloid deposition that often co-occurs with AD [2,3,44].”
Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept
Epelbaum, S., Genthon, R., Cavedo, E., Habert, M. O., Lamari, F., Gagliardi, G., Lista, S., Teichmann, M., Bakardjian, H., Hampel, H., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.003 · Cited by 77
“After the problematic experience with the vastly heterogeneous application of prodromal “MCI” concepts to research studies and drug development programs in AD [23] and failures of recent large-scale trials aiming at slowing down progression of the disease in patients with mildto-moderate AD [24,25], great interest has…”
BackgroundBelder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 85
Self-citationWalker, D., Lue, L. F., Paul, G., Patel, A., & Sabbagh, M. N. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1001490 · Cited by 77
“Most recent clinical trials with Ab antibodies have not shown significant benefit [11].”
BackgroundSelf-citationHampel, H., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S., & Lista, S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 75
“Biomarkers used as secondary outcomes included Pittsburgh compound B-PET amyloid burden imaging and CSF total tau and hyperphosphorylated-tau (p-tau) [73].”
BackgroundMethodInfluentialLessons from immunotherapy for Alzheimer disease
Wang, Y. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.44 · Cited by 87
Parasrampuria, D. A., Benet, L. Z., & Sharma, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0204-y · Cited by 93
“5 and 1 mg/kg doses compared to placebo (19).”
BackgroundPreclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
Panza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 75
“Very recently, in two double-blind, randomized, placebo-controlled Phase III trials on mild-to-moderate AD, one involving 1121 carriers of the APOE "4 allele and the other involving 1331 noncarriers, bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 we…”
BackgroundResultInfluentialTherapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 90
“Notably, the FDA approved a combined naxitamab-GM-CSF (granulocyte-macrophage colony-stimulating factor) therapy to treat refractory neuroblastoma in pediatric patients about the age of one and in adult patients [271].”
BackgroundMolecular Insights into Human Serum Albumin as a Receptor of Amyloid-β in the Extracellular Region
Choi, T. S., Lee, H. J., Han, J. Y., Lim, M. H., & Kim, H. I. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08584 · Cited by 80
Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
Gold, M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.005 · Cited by 75
“This article focuses on bapineuzumab and solanezumab because they share a mechanism of action (passive clearance of amyloid b, although targeting different portions of the peptide) and they both completed large Phase III trials that failed to detect clinically relevant treatment effects [31,32].”
BackgroundUpdate on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 75
“Consequently, biomarkers that detect and monitor biochemical effects of the drug are common in the early development of an AD drug [30].”
BackgroundSelf-citationEvolving new-age strategies to transport therapeutics across the blood-brain-barrier
Choudhari, M., Hejmady, S., Narayan Saha, R., Damle, S., Singhvi, G., Alexander, A., Kesharwani, P., & Kumar Dubey, S. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120351 · Cited by 74
Bouter, Y., López‐Noguerola, J. S., Tucholla, P., Crespi, G. A. N., Parker, M. W., Wiltfang, J., Miles, L. A., & Bayer, T. A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1489-x · Cited by 79
“However, large-scale phase three clinical trials were discontinued in 2012 as treatment evoked vasogenic edema and did not improve measures of cognitive decline in mild or moderate AD patients relative to placebo controls [9, 60, 69].”
BackgroundLu, K. P., Kondo, A., Albayram, Ö., Herbert, M. K., Liu, H., & Zhou, X. Z. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2027 · Cited by 78
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Immunotherapy for Alzheimer’s disease: past, present and future
Spencer, B., & Masliah, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00114 · Cited by 72
Webster, L., Groskreutz, D., Grinbergs-Saull, A., Howard, R., O’Brien, J. T., Mountain, G., Banerjee, S., Woods, B., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 74
“This may be important, as previous failed studies of immunotherapy in AD have found that around one-third of subjects with supposed AD did not have any evidence of increased brain amyloid.(122) Third, imaging is used to ensure that inclusion criteria are met, for example the absence of multiple microbleeds on MRI for…”
BackgroundTreatment strategies in Alzheimer’s disease: a review with focus on selenium supplementation
Aaseth, J., Alexander, J., Bjørklund, G., Hestad, K. A., Dušek, P., Roos, P. M., & Alehagen, U. (2016) · BioMetals · doi:10.1007/s10534-016-9959-8 · Cited by 79
James, M. L., Belichenko, N. P., Shuhendler, A. J., Höhne, A., Andrews, L., Condon, C., Nguyen, T. V., Reiser, V., Jones, P. A., Trigg, W., et al. (2017) · Theranostics · doi:10.7150/thno.17666 · Cited by 78
Atrial fibrillation, cognition and dementia: A review
Aldrugh, S., Sardana, M., Henninger, N., Saczynski, J. S., & McManus, D. D. (2017) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.13261 · Cited by 78
Hey, J. A., Kocis, P., Hort, J., Abushakra, S., Power, A., Vyhnálek, M., Yu, J. Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 71
Snow, A. D., Castillo, G. M., Nguyen, B. P., Choi, P. Y., Cummings, J. A., Cam, J. A., Hu, Q., Lake, T. P., Pan, W., Kastin, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38645-0 · Cited by 82
Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72
Villemagne, V. L., Rowe, C. C., Barnham, K. J., Cherny, R., Woodward, M., Bozinosvski, S., Salvado, O., Bourgeat, P., Perez, K., Fowler, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.001 · Cited by 71
“Comparison of the IMAGINE study PiB results with the reported PiB results of the bapineuzumab trial [22,36], and the florbetapir results from the”
MethodResultKenny, A., McArdle, H., Calero, M., Rabano, A., Madden, S. F., Adamson, K., Forster, R., Spain, E., Prehn, J. H. M., Henshall, D. C., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3429882 · Cited by 71
“The advanced stages of AD, at which clinical trials are applied, are often cited as a major contributor to the serial failures of AD therapeutic trials [3,4].”
BackgroundTherapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 78
Ishida, K., Yamamoto, M., Misawa, K., Nishimura, H., Misawa, K., Ota, N., & Shimotoyodome, A. (2020) · Neuroscience Research · doi:10.1016/j.neures.2019.05.001 · Cited by 72
The role of the immune system in driving neuroinflammation
Ní Chasaide, C., & Lynch, M. A. (2020) · Brain and Neuroscience Advances · doi:10.1177/2398212819901082 · Cited by 72
“Two of these trials that assessed solanezumab and bapineuzumab did not meet primary end points in improving clinical outcomes (Doody et al., 2014; Salloway et al., 2014; Vandenberghe et al., 2016).”
BackgroundAssociation of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease
Qian, J., Betensky, R. A., Hyman, B. T., & Serrano-Pozo, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011883 · Cited by 71
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J., Blennow, K., Johnson, K., Keeley, M., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P., & Vellas, B. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.14 · Cited by 71
Self-citationGao, F., Zhao, J., Liu, P., Ji, D., Zhang, L., Zhang, M., Li, Y., & Xiao, Y. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.09.098 · Cited by 71
Engineering antibody and protein therapeutics to cross the blood–brain barrier
Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 91
“Moreover, bapineuzumab failed to show benefits in the primary outcomes in a large phase 3 study comprising 1121 carriers and 1331 noncarriers with mild to moderate AD [27].”
Ma, Y., Zhang, S., Li, J., Zheng, D.-M., Guo, Y., Feng, J., & Ren, W.-D. (2014) · Medicine · doi:10.1097/md.0000000000000150 · Cited by 69
“Therefore, proper application of (11)C-PIB-PET would be useful to predict the conversion of MCI, which may have many prospects in clinical practice.(14,15) Some longitudinal studies with different follow-up durations have suggested that (11)C-PIB-PET may play a role in stratifying patients with MCI into their risk of…”
MethodPonezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study
Landen, J. W., Andreasen, N., Cronenberger, C. L., Schwartz, P. F., Börjesson‐Hanson, A., Östlund, H., Sattler, C. A., Binneman, B., & Bednar, M. M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.003 · Cited by 69
“In studies of bapineuzumab, PIB showed significant differences in amyloid burden between the treatment and control groups; there were also significant differences in CSF p-tau concentrations between the two groups among patients who were carriers of the APOE ε4 allele [4].”
BackgroundMann, A. P., Scodeller, P., Hussain, S., Braun, G. B., Mölder, T., Toome, K., Ambasudhan, R., Teesalu, T., Lipton, S. A., & Ruoslahti, E. I. (2017) · Nature Communications · doi:10.1038/s41467-017-01096-0 · Cited by 79
Gadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 68
Arrighi, H. M., Barakos, J., Barkhof, F., Tampieri, D., Jack, C., Melançon, D., Morris, K., Ketter, N., Liu, E., & Brashear, H. R. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309493 · Cited by 67
Self-citationFarzaei, M. H., Bahramsoltani, R., Abbasabadi, Z., Braidy, N., & Nabavi, S. M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27289 · Cited by 75
“However, the results obtained from two randomized double‐blind clinical trials revealed that bapineuzumab has the similar therapeutic effect to the placebo group (Salloway et al., 2014).”
BackgroundResultTherapeutic noninvasive brain stimulation in Alzheimer's disease and related dementias
Buss, S. S., Fried, P. J., & Pascual‐Leone, Á. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000669 · Cited by 75
“Recent drug trial failures for Alzheimer’s disease and related dementias (ADRD) have left the field with a lack of disease-modifying therapies [5,6].”
BackgroundHollow nanoarchitectures: Materials engineering, nanochemistry, and biomedical applications
Ghosh, S., Yang, C.-J., & Lai, J. (2025) · Progress in Materials Science · doi:10.1016/j.pmatsci.2025.101634 · Cited by 76
Antibodies and protein misfolding: From structural research tools to therapeutic strategies
Genst, E. D., Messer, A. C., & Dobson, C. M. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.08.016 · Cited by 77
“The fact that patients with mild forms of the disease did seem to receive modest benefits of the immunotherapy with bapineuzumab, shifted focus and efforts towards treating AD prior to or in the earliest stages of neurodegeneration, however recent phase III clinical trials of immunotherapy with both bapineuzumab and s…”
ResultGupta, V., Gupta, V. B., Chitranshi, N., Gangoda, S. V. S., Wall, R. V., Abbasi, M., Golzan, M., Dheer, Y., Shah, T. M., Avolio, A. P., et al. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2295-x · Cited by 75
“Monoclonal antibody therapy Bapineuzumab, solanezumab, GSK-933776, MABT-5102A [152, 153]”
InfluentialPenninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 75
Peptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 67
Sang, S., Pan, X., Chen, Z., Zeng, F., Pan, S., Liu, H., Jin, L., Fei, G., Wang, C., Ren, S., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0354-2 · Cited by 69
The Role of P2X7 Receptor in Alzheimer’s Disease
Francistiová, L., Bianchi, C., Di Lauro, C., Sebastián-Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00094 · Cited by 69
Caregivers as Therapeutic Agents in Dementia Care
Gitlin, L. N., & Hodgson, N. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417046-9.00017-9 · Cited by 96
Potential Utility of Retinal Imaging for Alzheimer’s Disease: A Review
Liao, H., Zhu, Z., & Peng, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00188 · Cited by 74
Dukart, J., Sambataro, F., Bertolino, A., & Initiative, F. T. A. D. N. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150570 · Cited by 68
Bales, K. R., O’Neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., Wood, K. M., Volfson, D., Cirrito, J. R., Han, B.-H., et al. (2016) · Brain · doi:10.1093/brain/awv313 · Cited by 68
“Disappointingly, various anti-amyloid-b immunotherapies have not demonstrated clinical efficacy in subjects with Alzheimer's disease who are diagnosed with mild to moderate disease in recently completed phase 3 trials (Salloway et al., 2014a, b).”
Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
Vilaplana, E., Rodriguez-Vieitez, E., Ferreira, D., Montal, V., Almkvist, O., Wall, A., Lleó, A., Westman, E., Graff, C., Fortea, J., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009405 · Cited by 69
Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 77
Kile, S., Au, W., Parise, C., Rose, K., Donnel, T., Hankins, A., Chan, M., & Ghassemi, A. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311486 · Cited by 67
Leonurine: From Gynecologic Medicine to Pleiotropic Agent
Li, Y., Lin, Y., Liu, X., Wang, L., Yu, M., Li, D., Zhu, Y. Z., & Du, M. (2019) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-019-3453-0 · Cited by 69
Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease
Relkin, N. R. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0041-4 · Cited by 75
“treatments, especially in light of the occurrence of meningoencephalitis in patients vaccinated with AN-1792 and the reports of Amyloid Related Imaging Abnormalities (ARIA) including micro-hemorrhages and vasogenic edema in patients treated with anti-amyloid monoclonals [4].”
Koychev, I., on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, R. N., Firouzian, A., Lawson, J., Zamboni, G., Ridha, B., Sahakian, B. J., Rowe, J. B., Thomas, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170129 · Cited by 69
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
Zhang, S., Smailagic, N., Hyde, C., Noel-Storr, A. H., Takwoingi, Y., McShane, R., & Feng, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010386.pub2 · Cited by 66
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Lopes Alves, I., Collij, L. E., Altomare, D., Frisoni, G. B., Saint‐Aubert, L., Payoux, P., Kivipelto, M., Jessen, F., Drzezga, A., Leeuwis, A., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12069 · Cited by 67
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 78
“All of these mAbs failed to show efficacy in the removal of amyloid and cognition, probably due to their weaker ability to inhibit A β aggregation (Honig et al., 2018; Linse and Scheidt, 2020; Ostrowitzki et al., 2022; Salloway et al., 2014).”
Johannesson, M., Söderberg, L., Zachrisson, O., Fritz, N., Kylefjord, H., Gkanatsiou, E., Button, E. B., Svensson, A.-S., Rachalski, A., Nygren, P., et al. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103949 · Cited by 75
Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease
Carlson, C., Siemers, E., Hake, A., Case, M., Hayduk, R., Suhy, J., Oh, J., & Barakos, J. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.004 · Cited by 65
“Similar to the phase 2 studies, most ARIA-E cases in the phase 3 studies occurred within the first 3 doses (w39 weeks or 273 days) [6].”
BackgroundResultInfluentialZafeiris, D., Rutella, S., & Ball, G. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.02.001 · Cited by 74
Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system
Quitterer, U., & AbdAlla, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.014 · Cited by 77
Hull, M., Sadowsky, C., Arai, H., Leterme, G. L. P., Holstein, A., Booth, K., Peng, Y., Yoshiyama, T., Suzuki, H., Ketter, N., et al. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170117101537 · Cited by 65
Self-citationMielke, M. M. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.030023 · Cited by 63
“This is problematic because 10–30% of clinically defined AD dementia patients do not have AD pathology at autopsy (19, 20).”
BackgroundDissecting the complexities of Alzheimer disease with in vitro models of the human brain
Blanchard, J., Victor, M. B., & Tsai, L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00578-6 · Cited by 74
Immunotherapies for Alzheimer’s Disease—A Review
Valiukas, Z., Ephraim, R., Tangalakis, K., Davidson, M., Apostolopoulos, V., & Feehan, J. (2022) · Vaccines · doi:10.3390/vaccines10091527 · Cited by 82
“Thirteen phase III trials using the mAbs bapineuzumab [70], solanezumab [71], gantenerumab [72,73], and crenezumab [74] have been conducted in recent years, however, all were discontinued due to a lack of efficacy on improving cognitive function (Table 1).”
BackgroundAgadjanyan, M. G., Petrovsky, N., & Ghochikyan, A. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1884 · Cited by 64
“phase III trials of the anti-Ab based monoclonal antibodies, bapineuzumab and solanezumab [92,93] also suggested that to be effective immunotherapy should be initiated at earlier stages of AD pathology.”
BackgroundBroadstock, M., Ballard, C., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 58
“Two Phase III trials of bapineuzumab, a humanised monoclonal antibody directed against Ab, in either carriers of the apolipoprotein E (APOE) e4 allele or non-carriers, did not show any improvement in clinical outcomes [16].”
BackgroundMultiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy
Landen, J. W., Cohen, S., Billing, C. B., Cronenberger, C., Styren, S., Burstein, A. H., Sattler, C., Lee, J., Jack, C. R., Kantarci, K., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.003 · Cited by 64
“Although the approach initially appeared promising, bapineuzumab did not improve clinical outcomes [4].”
BackgroundResultCollij, L. E., Konijnenberg, E., Reimand, J., ten Kate, M., den Braber, A., Alves, I. L., Zwan, M. D., Yaqub, M. M., van Assema, D. M. E., Wink, A. M., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.211532 · Cited by 66
“Our results may have consequences for drug-intervention studies focused on early populations, since using the visual assessment of SUVr images as an inclusion criterion could result in false-positive inclusion due to the observed overestimation of cortical amyloid burden (32,33).”
Ahsan, A. U., Sharma, V. L., Wani, A., & Chopra, M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01969-4 · Cited by 71
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 76
Immune Regulation of Antibody Access to Neuronal Tissues
Iwasaki, A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.004 · Cited by 73
“Recent results from four multicenter randomized double-blind, placebo-controlled, phase 3 trials of bapineuzumab (humanized monoclonal IgG1 anti-Aβ42 antibody (Aβ1–5)) showed no efficacy in treatment of AD disease [84, 85].”
Chiao, P., Bedell, B. J., Avants, B., Zijdenbos, A. P., Grand'Maison, M., O’Neill, P., O’Gorman, J., Chen, T., & Koeppe, R. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209130 · Cited by 63
Metadata
- Authors
- Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., & Brashear, H. R.
- Affiliations
- Brigham and Women's Hospital (US)
- UCL Queen Square Institute of Neurology (GB)
- Sahlgrenska University Hospital (SE)
- University of Pittsburgh (US)
- Veterans Health Administration (US)
- Columbia University (US)
- University of Rochester Medicine (US)
- NYU Langone Health (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- University of California San Diego (US)
- Pfizer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 322-333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4159618
- OpenAlex
- W2063808031
- Semantic Scholar
- e062a2c7d07a68f95ef3d0dad78aaa50b786274d
- Cited by
- 1,960
- References
- 35
- Citations by year
- 2026: 71 · 2025: 102 · 2024: 151 · 2023: 131 · 2022: 127 · 2021: 144 · 2020: 180 · 2019: 173 · 2018: 162 · 2017: 184 · 2016: 200 · 2015: 208 · 2014: 123
- FWCI
- 158.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK2 BX001820)
- National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
- Medical Research Council (MR/L501517/1, MR/L010305/1, MR/K013041/1)
- National Institute on Aging (P30AG008051, P50AG008702, P50AG005136, P50AG005134, P30AG062421)
- National Institute of Neurological Disorders and Stroke (R01NS080820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, APOE ε4 carriers, amyloid-related imaging abnormalities, amyloid PET, Pittsburgh compound B, phosphorylated tau, cognitive impairment, functional disability, treatment discontinuation, mild to moderate Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition, Double-Blind Method, Edema, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Phosphorylation, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Positron-Emission Tomography, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.